Drug Trial Radar · NCT07737600
A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
316
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Lepu Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of MRG007 combination therapy in patients with advanced colorectal cancer.
Conditions
- Advanced Colorectal Cancer
Interventions
MRG007Drug
MRG007 will be administrated as specified in the protocol.
5-Fluorouracil / Leucovorin CalciumDrug
5-Fluorouracil / Leucovorin Calcium will be administrated as specified in the protocol.
BevacizumabDrug
Bevacizumab will be administrated as specified in the protocol.
OxaliplatinDrug
Oxaliplatin will be administrated as specified in the protocol.
PD-1/VEGF antibodyDrug
PD-1/VEGF antibody will be administrated as specified in the protocol.
CapecitabineDrug
Capecitabine will be administrated as specified in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT)Time frame: From the first dose to 30 days after the last dose
- Serious Adverse Events (SAEs)Time frame: From the first dose to 30 days after the last dose
- Adverse Event (AE)Time frame: From the first dose to 30 days after the last dose
- Recommended Phase 2 Dose(RP2D) and/or Maximum Tolerated Dose (MTD)Time frame: From the first dose to 30 days after the last dose
- Objective Response Rate (ORR)Time frame: Assessments will be performed every 6 weeks (± 7 days) following the first dose.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.